Events

News Release



Printer Friendly Version View printer-friendly version
« Back
Rigel to Present at Jefferies 2017 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., June 1, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Ryan Maynard, the company's chief financial officer, is scheduled to present a company overview at the Jefferies 2017 Global Healthcare Conference on Wednesday, June 7, 2017 at 11:30am EDT

To access the live webcast of the presentation or the subsequent archived recording, log on to www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software download that may be necessary.

About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of novel, targeted drugs in the therapeutic areas of immunology, oncology and immuno-oncology. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's current clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor in a number of indications. The company submitted an NDA to the FDA for fostamatinib in patients with chronic or persistent immune thrombocytopenia (ITP) in April 2017. Rigel is also conducting Phase 2 clinical studies with fostamatinib in IgA nephropathy (IgAN) and autoimmune hemolytic anemia (AIHA). In addition, Rigel has product candidates in development with partners BerGenBio AS, Daiichi Sankyo and Aclaris Therapeutics.

Contact: Raul Rodriguez
Phone: 650.624.1302
Email: invrel@rigel.com

Media Contact: Susan C. Rogers, Rivily, Inc.
Phone: 650.430.3777
Email: susan@rivily.com

Rigel Pharmaceuticals, Inc. (PRNewsFoto/Rigel Pharmaceuticals, Inc.)

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/rigel-to-present-at-jefferies-2017-global-healthcare-conference-300466864.html

SOURCE Rigel Pharmaceuticals, Inc.